LYELL IMMUNOPHARMA INC.
-
USD
(-)
- 15 min delayed data - NASDAQ Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | LYEL |
| ISIN: |
LYELL IMMUNOPHARMA INC. news, videos and press releases
For more news please use our advanced search feature.
LYELL IMMUNOPHARMA INC. - More news...
LYELL IMMUNOPHARMA INC. - More news...
- 03/11/2025 - 20:05 Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
- 02/18/2025 - 21:05 Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
- 01/09/2025 - 14:00 Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
- 12/10/2024 - 02:00 Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
- 11/07/2024 - 21:05 Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
- 11/05/2024 - 14:30 Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
- 10/31/2024 - 20:00 Lyell Immunopharma Completes Acquisition of ImmPACT Bio
- 10/24/2024 - 20:00 Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
- 10/04/2024 - 13:00 Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- 09/24/2024 - 20:05 Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
- 08/28/2024 - 20:05 Lyell Immunopharma Announces Participation in September Investor Conferences
- 08/07/2024 - 20:05 Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
- 06/26/2024 - 11:00 Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
- 06/03/2024 - 20:05 Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
- 05/07/2024 - 20:05 Lyell Immunopharma to Participate in BofA Securities Health Care Conference
- 05/06/2024 - 12:00 Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
- 03/05/2024 - 21:30 Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
- 02/28/2024 - 21:05 Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
- 02/26/2024 - 21:05 Lyell Immunopharma Announces Participation in March Investor Conferences
- 01/03/2024 - 21:05 Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
- 11/09/2023 - 21:05 Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
- 11/07/2023 - 21:05 Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
- 10/31/2023 - 13:00 Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
- 09/27/2023 - 13:00 Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- 09/11/2023 - 12:00 Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
- 08/31/2023 - 20:05 Lyell Immunopharma to Participate in Upcoming Investor Conferences
- 08/08/2023 - 20:05 Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
- 07/05/2023 - 20:05 Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer
- 06/07/2023 - 20:05 Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
- 05/04/2023 - 20:05 Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
